Financial Performance - Net income for the second quarter of fiscal 2025 was $2.7 million, or $0.29 per diluted share, down from $4.6 million, or $0.48 per diluted share in the same period of 2024[3] - Net income for the three months ended March 31, 2025, was $2,735,000, a decrease of 40.19% from $4,562,000 in the same period of 2024[31] - Basic earnings per share for the three months ended March 31, 2025, was $0.29, down from $0.48 in 2024, representing a decline of 39.58%[31] Interest Income and Expense - Total interest income for the second quarter of fiscal 2025 was $25.6 million, slightly down from $25.7 million year-over-year, while the yield on average interest-earning assets increased to 5.01% from 4.95%[6] - Total interest income for the three months ended March 31, 2025, was $25,632,000, a slight decrease of 0.07% compared to $25,650,000 in the same period of 2024[31] - Interest expense increased to $11.4 million for the second quarter of 2025, compared to $10.8 million in the same period of 2024, with the cost of interest-bearing liabilities rising to 2.80% from 2.58%[8] - Net interest income before release of credit losses was $14.2 million in the second quarter of 2025, down from $14.9 million in the second quarter of 2024[10] - Net interest income after the release of credit losses for the six months ended March 31, 2025, was $29,003,000, down 5.25% from $30,611,000 in 2024[31] - The net interest rate spread decreased to 2.21% for the three months ended March 31, 2025, compared to 2.37% in 2024[32] - The net interest margin for the three months ended March 31, 2025, was 2.78%, down from 2.87% in 2024[32] Assets and Loans - Total assets were $2.168 billion at March 31, 2025, a decrease from $2.188 billion at September 30, 2024[18] - Total assets as of March 31, 2025, were $2,183,673,000, a slight decrease of 0.04% from $2,191,544,000 in 2024[32] - Total net loans increased to $1.76 billion at March 31, 2025, up from $1.74 billion at September 30, 2024, with residential real estate loans rising to $734.8 million[19] Nonperforming Assets and Deposits - Nonperforming assets were $11.7 million, or 0.54% of total assets, at March 31, 2025, compared to $12.2 million, or 0.56% at September 30, 2024[20] - Total deposits increased to $1.69 billion at March 31, 2025, compared to $1.63 billion at September 30, 2024, with core deposits at $1.04 billion[21] Capital and Regulatory Compliance - The Tier 1 capital ratio was 10.3% at March 31, 2025, exceeding regulatory standards for a well-capitalized institution[23] Mergers and Acquisitions - The Company announced a merger agreement with CNB Financial Corporation, which received formal approval from shareholders on April 15, 2025[5] Noninterest Income and Expense - Total noninterest income increased to $2,017,000 for the three months ended March 31, 2025, compared to $2,004,000 in 2024, reflecting a growth of 0.65%[31] - Total noninterest expense rose to $12,807,000 for the three months ended March 31, 2025, up 9.29% from $11,714,000 in 2024[31] Shares Outstanding - Average shares outstanding - diluted for the three months ended March 31, 2025, was 9,560,278, an increase from 9,513,798 in 2024[32]

Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, March 24, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises ESSA Pharma Inc. ("ESSA Pharma" or the "Company") (NASDAQ: EPIX) investors of a class action representing investors that bought securities between December 12, 2023 and October 31, 2024, inclusive (the "Class Period"). ESSA Pharma investors have until March 25, 2025 to file a lead plaintiff motion. Investors are encouraged to contact attorney ...

NEW YORK, March 24, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of ESSA Pharma Inc. (NASDAQ: EPIX).Shareholders who purchased shares of EPIX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/essa-pharma-inc-loss-submission-form/?id=137676&from=4CLASS PERIOD: December 12, 2023 t ...

NEW YORK, March 20, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of ESSA Pharma Inc. (NASDAQ: EPIX).Shareholders who purchased shares of EPIX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/essa-pharma-inc-loss-submission-form/?id=137063&from=4CLASS PERIOD: December 12, 2023 t ...

NEW YORK, March 18, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in ESSA Pharma Inc. ("ESSA Pharma Inc." or the "Company") (NASDAQ: EPIX) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of ESSA Pharma Inc. investors who were adversely affected by alleged securities fraud between December 12, 2023 and October 31, 2024. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/essa-pharma ...

NEW YORK, March 17, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of ESSA Pharma Inc. (NASDAQ: EPIX). Shareholders who purchased shares of EPIX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/essa-pharma-inc-loss-submission-form/?id=136041&from=3 CLASS PERIOD: December 12 ...

Core Viewpoint - A class action securities lawsuit has been filed against ESSA Pharma Inc. alleging securities fraud that affected investors between December 12, 2023, and October 31, 2024 [1][2]. Group 1: Allegations of Fraud - The lawsuit claims that the defendants made false statements regarding the efficacy of masofaniten in combination with enzalutamide, suggesting it had no clear benefit over enzalutamide alone [2] - It is alleged that masofaniten was less effective in treating prostate cancer than previously communicated to investors [2] - The M-E Combination Study was reportedly unlikely to meet its prespecified Phase 2 primary endpoint, contradicting the defendants' public statements [2] - Defendants are accused of overstating masofaniten's clinical, regulatory, and commercial prospects, leading to materially false and misleading public statements [2] Group 2: Legal Process and Participation - Investors who suffered losses during the specified timeframe have until March 25, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require this role [3] - Class members may be entitled to compensation without any out-of-pocket costs or fees, indicating no financial obligation to participate [3] Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States [4] - The firm has over 70 employees dedicated to serving clients in complex securities litigation [4]

NEW YORK, March 6, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of ESSA Pharma Inc. (NASDAQ: EPIX).Shareholders who purchased shares of EPIX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/essa-pharma-inc-loss-submission-form/?id=134039&from=4 CLASS PERIOD: December 12, 2023 t ...

Core Viewpoint - ESSA Pharma Inc. is facing a class action lawsuit due to allegations of misleading statements regarding the efficacy of its drug masofaniten in combination with enzalutamide for prostate cancer treatment [3]. Group 1: Class Action Details - The class action represents investors who purchased ESSA Pharma securities between December 12, 2023, and October 31, 2024 [1]. - Investors have until March 25, 2025, to file a lead plaintiff motion [1]. Group 2: Allegations Against ESSA Pharma - The complaint claims that ESSA Pharma made materially false and misleading statements about masofaniten's effectiveness when combined with enzalutamide, indicating no clear efficacy advantage over enzalutamide alone [3]. - The M-E Combination Study, which assessed masofaniten's performance, is unlikely to meet its primary endpoint as specified in Phase 2 [3]. - The company allegedly overstated masofaniten's clinical, regulatory, and commercial potential, leading to misleading public statements throughout the class period [3].

NEW YORK, Feb. 28, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in ESSA Pharma Inc. ("ESSA Pharma Inc." or the "Company") (NASDAQ: EPIX) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of ESSA Pharma Inc. investors who were adversely affected by alleged securities fraud between December 12, 2023 and October 31, 2024. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/essa-pharma- ...